New strains in our 2026 catalog

Dear partners,

Janvier Labs is proud to help advance the frontiers of translational research by introducing several key innovative models to its portfolio. Designed to provide superior physiological relevance, these advanced tools – including the B6h GLP1R, B6h CA4, B6h SORT1, NXG MHC DKO, and NXG FcClarity – empower researchers to evaluate human-specific therapeutics with unprecedented precision.

B6h GLP1R

The B6h GLP1R mouse expresses the human glucagon-like peptide-1 receptor under physiological control on a C57BL/6 background. It enables precise evaluation of human-specific GLP-1R agonists, biased ligands, and antibody-based therapeutics. This model supports translational metabolic research in obesity, diabetes, and cardiometabolic disease.

B6h CA4

The B6h CA4 model carries the human carbonic anhydrase IV sequence replacing the murine counterpart. It is designed to assess species-specific pharmacology, antibody binding, and safety of CA4-targeting molecules. Maintained on a stable C57BL/6 background, it ensures reproducibility in renal, pulmonary, and vascular research applications.

B6h SORT1

The B6h SORT1 mouse expresses the human sortilin-1 receptor in place of the murine gene. Given SORT1’s involvement in lipoprotein metabolism and cardiovascular risk, this model enables evaluation of human-specific biologics and gene-targeting strategies. It is particularly relevant for atherosclerosis, lipid homeostasis, and cardiometabolic drug discovery programs.

NXG MHC DKO

Based on the NXG mouse background, the NXG MHC DKO lacks both murine MHC class I and II expression. This dual knockout improves human immune cell engraftment by reducing xenogeneic antigen presentation. It is optimized for advanced humanization studies in immuno-oncology and cell therapy research.

NXG FcClarity

Derived from the NXG mouse platform, NXG FcClarity is engineered to minimize murine Fc receptor interactions. This modification reduces non-specific binding of human IgG, improving interpretation of antibody efficacy and safety. The model enhances translational predictivity in therapeutic antibody and immuno-oncology development.

By integrating these cutting-edge models into your research programs, Janvier Labs continues its commitment to delivering excellence in preclinical solutions. Whether your focus is on metabolic disorders, immuno-oncology, antibody development or other areas, we are excited to support your 2026 discovery goals with these high-performance translational platforms.

Agenda